poisar

Stocks · News reference

Cantor Fitzgerald Reiterates Overweight Rating for ArriVent BioPharma

Fiscal.ai

Cantor Fitzgerald reaffirmed an Overweight rating for ArriVent BioPharma, Inc. on November 12, 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading